Last updated: May 29, 2026
Tapentadol ER (Nucynta ER; extended-release tablets) is supplied through a limited set of upstream API and downstream dosage-form manufacturers, with the practical “supplier” universe in US commercialization typically tied to the labeled NDA holder supply chain plus any contract manufacturing partners shown on regulatory and product-labeling records.
Which companies supply Nucynta ER (tapentadol extended-release) in the US?
Answer: The labeled product’s supply is attributable to the NDA holder and its manufacturing network listed in FDA records and on the US label, with finished-dose supply typically executed by contract manufacturers and API supplied by specialized chemical manufacturers.
Who holds the labeled manufacturing responsibilities for Nucynta ER?
Key manufacturing/supply entities are those that appear as manufacturer and/or packager on the US prescription label and those listed in FDA drug application manufacturing sections (CMC).
Labeled supply-chain mapping (what to look for)
- Finished-dose manufacturing site(s): Company name on the label under “Manufactured for” / “Manufacturing by” and associated site address on carton labeling.
- API sourcing: Company name may not appear on the US label; API suppliers are more reliably found in FDA CMC sections, DMF-linked correspondence, and quality agreements referenced in regulatory filings.
- Packager/distributor: Often a separate entity that repacks/dispenses for commercial distribution.
What upstream API suppliers make tapentadol for Nucynta ER?
Answer: Tapentadol API is supplied by specialty chemical manufacturers that support controlled-substance risk, high-purity synthesis, and validated ER-grade specs.
API supply indicators used in diligence
- DMF or API registration links (if referenced in regulatory review).
- Batch release testing / site quality agreements aligned to ER dosage-form release requirements.
- Secured supply chain capability due to tapentadol’s controlled-substance status.
API-to-ER formulation compatibility constraints
Nucynta ER is an extended-release oral solid. API suppliers must meet:
- particle size and polymorph control for consistent ER matrix behavior
- impurity limits aligned to FDA specifications
- stability profile aligned to ER processing and packaging
Which contract manufacturing organizations (CMOs) make Nucynta ER tablets?
Answer: Finished-dose production is commonly executed by CMOs or affiliated manufacturing sites with scale-up experience for ER matrix tablets and controlled-substance compliance.
CMO identification approach used in IP and regulatory work
- match manufacturing site addresses on the label to corporate entities
- confirm if site is owned/operated by the NDA holder or a CMO under a quality agreement
- cross-check with post-approval supplements that change manufacturing location or process parameters
How do you verify Nucynta ER suppliers via FDA label and Orange Book records?
Answer: Use FDA’s public product labeling plus Orange Book and drug application records to identify manufacturer and dosage form, then trace manufacturing changes through supplements.
What records typically contain the supplier footprint
- US prescribing information (label): identifies manufacturer/packager entities for the marketed product.
- Orange Book: confirms the approved dosage forms and application holders tied to exclusivity and patents, which helps anchor the manufacturing network.
- FDA review documents and approval history: show manufacturing changes (CMC supplements) and the manufacturing sites in the approval record.
- Drug facility registrations: can narrow which sites are permitted to produce/manufacture tapentadol ER dosage forms.
What patents or exclusivity affect alternative supplier strategies for Nucynta ER?
Answer: Tapentadol ER supply substitution is constrained by the patent estate around the extended-release formulation, manufacturing/process, and any method-of-use claims, plus FDA exclusivity tied to the NDA reference.
Supplier risk points for generics and “authorized” manufacturing
- ER formulation patents can limit redesign options for the same release profile.
- process patents can restrict certain tablet compression/coating/matrix approaches.
- method-of-use patents can restrict labeling and some clinical claims even if the dosage form is approved.
- Orange Book-listed exclusivities can delay approval routes tied to reference product data protection.
What generic or biosimilar entry risks exist for tapentadol ER suppliers?
Answer: Generic entry is usually the key “supplier substitution” pathway for small-molecule ER products. For tapentadol ER, entry risk is driven by:
- Orange Book patent barriers (blockers and settlement dynamics)
- FDA approval pathway selection (505(j) generics)
- ability to meet ER performance specifications without infringing formulation/process patents
Practical diligence items for supplier selection
- confirm whether prospective generic supply chains are cleared on listed patents
- check whether any settlement agreements restrict launch timing or product features
- confirm whether the generic’s release characteristics are within FDA-approved specs
What manufacturing/IP barriers can block new Nucynta ER suppliers?
Answer: Supply-chain barriers for ER controlled-substance products often include both IP and CMC constraints:
- tablet matrix formulation and release mechanism controlled by patents
- controlled-substance licensing and security requirements
- validated ER performance, including dissolution and exposure profile matching
CMC barriers that impact supplier onboarding
- validated ER manufacturing process and batch consistency
- stability and shelf-life packages compatible with ER tablet integrity
- packaging and labeling controls for a controlled-substance product
Commercial landscape: who can realistically be a “supplier” for Nucynta ER?
Answer: Commercially relevant “suppliers” in US market practice split into:
- NDA holder/manufacturer network for the reference product
- CMOs contracted by the NDA holder to produce or package finished product
- Generic manufacturers (and their CMOs) once patents and regulatory barriers clear
Where suppliers appear in commercial procurement
- tenders and distributor agreements usually list:
- “brand product” manufacturer on regulatory labels
- contract manufacturing facility for the batch supply
- packager for secondary packaging and distribution-ready units
Key takeaways
- Nucynta ER supply is anchored to the NDA holder’s labeled manufacturing and packaging entities shown in US prescribing information and FDA records.
- Upstream tapentadol API suppliers are identified more reliably via CMC/DMF-linked regulatory records than via consumer-facing labeling.
- New supplier entry (generic procurement or contract manufacturing) is constrained by ER-specific formulation/process IP plus controlled-substance CMC and security requirements.
FAQs
1) What does the Nucynta ER label say about the manufacturer and packager?
Check the “Manufactured for” / “Manufactured by” and “Packaged by” sections in the latest US prescribing information and carton labeling, which identify the direct labeled supply entities.
2) Which FDA databases show manufacturing site changes for tapentadol ER tablets?
Use the FDA approval history for the NDA and supplement records that reflect manufacturing changes, plus facility registration records to map permitted sites.
3) How can I identify the tapentadol API supplier for Nucynta ER?
Trace DMF references and CMC-linked API sourcing information in FDA regulatory materials tied to the NDA, since the US label usually focuses on finished-dose manufacturers.
4) What generic approval pathway typically applies to tapentadol ER?
Tapentadol ER is usually pursued via the Abbreviated New Drug Application (505(j)) pathway for generics, with Orange Book patents and exclusivity driving the timing.
5) What supplier onboarding requirements matter most for ER controlled-substance tablets?
Focus on controlled-substance compliance, validated ER tablet manufacturing capability, dissolution/exposure performance, and stability/packaging integrity validated to FDA specifications.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. Food and Drug Administration. Approved Drug Products (NDA review and labeling records for Nucynta ER).
- U.S. Food and Drug Administration. Drug Registration and Listing System (DRLS) and facility registration records.
